GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (STU:C26) » Definitions » Price-to-Free-Cash-Flow

CellaVision AB (STU:C26) Price-to-Free-Cash-Flow : 33.19 (As of Dec. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is CellaVision AB Price-to-Free-Cash-Flow?

As of today (2024-12-12), CellaVision AB's share price is €18.82. CellaVision AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €0.57. Hence, CellaVision AB's Price-to-Free-Cash-Flow Ratio for today is 33.19.

The historical rank and industry rank for CellaVision AB's Price-to-Free-Cash-Flow or its related term are showing as below:

STU:C26' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.28   Med: 71.08   Max: 828.93
Current: 32.86

During the past 13 years, CellaVision AB's highest Price-to-Free-Cash-Flow Ratio was 828.93. The lowest was 14.28. And the median was 71.08.

STU:C26's Price-to-Free-Cash-Flow is ranked better than
50% of 350 companies
in the Medical Devices & Instruments industry
Industry Median: 32.945 vs STU:C26: 32.86

CellaVision AB's Free Cash Flow per Share for the three months ended in Sep. 2024 was €0.09. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €0.57.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of CellaVision AB was 153.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 43.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 12.70% per year.

During the past 13 years, CellaVision AB's highest 3-Year average Free Cash Flow per Share Growth Rate was 491.10% per year. The lowest was -65.70% per year. And the median was 17.15% per year.


CellaVision AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for CellaVision AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Price-to-Free-Cash-Flow Chart

CellaVision AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.02 195.42 102.85 80.49 45.99

CellaVision AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.95 45.99 33.84 32.69 45.85

Competitive Comparison of CellaVision AB's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, CellaVision AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Price-to-Free-Cash-Flow falls into.



CellaVision AB Price-to-Free-Cash-Flow Calculation

CellaVision AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=18.82/0.567
=33.19

CellaVision AB's Share Price of today is €18.82.
CellaVision AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.57.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

CellaVision AB  (STU:C26) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


CellaVision AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.

CellaVision AB Headlines

No Headlines